GILD: $69 | another Breakthrough for Humanity | Loaded!from Ebola treatment to quick remedy for Corona
truly a mission worth funding and risking on
BIO
Bluebird Bio (NASDAQ: BLUE) Posing Strong Bearish TrendBLUE is currently trading above its 50-day and 200-day simple moving averages (SMA), indicating a bullish trend. However, the 50-day SMA is below the 200-day SMA, forming a death cross pattern, which is a bearish signal.
The 20-day exponential moving average (EMA) is also above the current price, acting as a resistance level. A break above the 20-day EMA could signal a continuation of the uptrend, while a break below the 50-day SMA could signal a reversal of the trend.
Earnings and Revenue: The earnings per share (EPS) of BLUE is expected to decline by 37.50% in the current quarter (Dec 2023) and increase by 333.30% in the next quarter (Mar 2024). The EPS for the current year (2023) is estimated to be -$11.7, which is a 59.10% decrease from the previous year (2022). The EPS for the next year (2024) is projected to be -$8.6, which is an 26.50% increase from the current year2. The revenue of BLUE is expected to decrease by 3.10% in the current quarter (Dec 2023) and increase by 9.00% in the next quarter (Mar 2024). The revenue for the current year (2023) is estimated to be $289.2 million, which is a 0.80% decrease from the previous year (2022). The revenue for the next year (2024) is forecasted to be $313.6 million, which is a 8.40% increase from the current year.
The technical analysis of BLUE shows that the stock is in a mixed trend, with some bullish and bearish signals. The stock is also facing low volatility and uncertain momentum. The earnings and revenue estimates suggest that the company is going through a challenging period, but might recover in the future.
DNA Ginko Bioworks; be ready bio-world!NYSE:DNA be ready for bio-world, bio-factory, biological food ingredients via cell programming!
Advise yourself smartly!
$LABP First Supply Test and VolumeCrazy volume on this one relative to it's history and .58 supply test and rejection but stock is still hovering above .4 resistance which is promising for longs.
I'm in at .3 and holding for .7 Target, to trim some along the way.
BIO | Medical Device Co | Good EntryBio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
$MIRM bear proof 👁🗨
*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management
My team entered Mirum Pharmaceuticals $MIRM today at $25 per share. Our take profit is $30. We also have a stop less set at $24
OUR ENTRY: $25
FIRST TAKE PROFIT: $30
STOP LOSS: $24
If you want to see more, please like and follow us @SimplyShowMeTheMoney
BIO long scenarioWe are finishing 1 to 5 Elliot wave theory and expecting price to bounce around 450$ zone.
Entry: 450 (institutional candle zone)
Invalidation 422 (Below buy zone)
Target: 644 (top of daily accumulation zone)
$AMGN LONG IDEA$AMGN is one of my favorite bio tech stocks as it has solidified its place as a winner over the years. They had a bit of a slowdown and consolidation over the past few years as they didn't have as much involvement with COVID, but certainly didn't lose too much value.
Watch for a 4hr close above $241.50 to send us back to $260+ over next few weeks.
CSTL - CONFLUENCE SUPPORT AT $37 IF IT GETS THEREAll,
Castle looks like it would bounce pretty huge here at $37 double support. However, not in a bad spot now to reverse. Just wait and see clerly taking a beating.
LLY trianglePulling back towards a potential buying zone ( 257.80 - 255.85)
Below that area we have a trendline that could also offer support.
Will wait for either a rejection off the buying zone or a break of the triangle
BNTX massive breakBreak is happening today, Could take it today or wait for an extra candle, I might wait
But chart looks pretty good
$MIRM november update*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Recap: My team entered $MIRM on 10/29/21 at $15.70 per share. Our first take profit is at $26.
Mirum Pharmaceuticals $MIRM released their 3rd quarter earnings today after market close. In this report they announced a loss of -$1.55 per share on revenue of $5.0 million. This earnings beat is staggering, especially when acknowledging the fact that the revenue consensus was only $0.8 million. $MIRM is still an under the radar company currently, but a revenue beat of 502.4% will definitely turn some heads. In addition, post-earnings five insiders accumulated a vast amount of shares. These insiders know what's coming, and lucky for us we do too. Our first take profit is honestly a huge underestimate of this companies potential, and in the future we may have to make some major adjustments.
This is a buy and throw away the key type of investment. My teams holding! Will you?
OUR ENTRY: $15.70
FIRST TAKE PROFIT: $26
If you want to see more, please like and follow us @SimplyShowMeTheMoney
PFETargeting 41$ .. Falling along with MRNA as vaccines should have less effect on peoples lives going forward.
MRNA chart will be posted next and that one should move down further than a company like Pfizer. Pfizer has a future, Moderna really does not.
ADMA - OBVIOUS BUY DUHHHAll,
Just look at larger timeframes and price targets + last two EPS. I'm going in with 5% stop loss here. No reason not to. Undervalued, float is mediocre nothing great, but absolutely worth a stab here.
$EDSAEdesa Biotech Inc (NASDAQ: EDSA) is surging higher Monday after the company announced positive Phase 2 data of its monoclonal antibody in hospitalized COVID-19 patients. Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over standard of care.
An independent Data and Safety Monitoring Board concluded that "a clinically important efficacy signal" was detected and that the study "met its objective." The DSMB recommended continuation of the study into a Phase 3 trial.
"The strong effect in reducing death in the most critically ill hospitalized patients who have been treated with systemic corticosteroids, including dexamethasone, and IL-6 inhibitors, shows the potential life-saving impact of this drug, irrespective of SARS-CoV-2 variant," said Par Nijhawan, CEO of Edesa Biotech.
Edesa Biotech is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of sPLA2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, a monoclonal antibody candidate. It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
BNGO - Time to shoot up!Hey everyone,
I hope you are doing fantastic!
$BNGO has presented us with an amazing set-up inside a channel.
We are currently sitting at the bottom of it and we have 2 TP ($8 and $10)
An amazing Risk-Reward with SL just above the channel.
I wish you all happy trading!
LABD break outI have been tackling LABD/LABU day in and day out. I have somehow made some profit week by week. I am trying to figure out which was the better trade as I think it has come to the tipping point. I believe LABD is the winner. I see bearish sentiment in the short term market and I see an inverse head and shoulders or a cup and handle formation. On LABU I confirmed it because whichever way I look at it it is the opposite, head and shoudler pattern, inverse cup and handle.
$BNTX Long term PT 950 and higher$BNTX Leaps Calls 680 Mar 17th 2023 Returns +403%
The FDA approval of Pfizer’s COVID-19 vaccine is a ‘critical step forward in vaccine confidence’: Doctor
MIRO Miromatrix Medical Price TargetMiromatrix Medical Inc. engages in the development of biological human organs to solve the chronic shortage of transplantable organs.
114,000 people in the U.S. are waiting for a life-saving organ transplant, and more than half will die due to a lack of available organs.
Miromatrix Medical trial is expected to begin in the second half of 2022 and will assess the function of a bioengineered liver in humans via an external application.
if it succeeds, the opportunity to buy the stock at these prices will be history.
The Market Cap of MIRO is just 214.74Mil
On 7/19/2021 Craig Hallum brokerage Initiated Coverage with a Buy rating and a $22.00 price target
ABCL - 20-30% UPSIDE - LONGAll,
ABCL is for massively oversold on weekly down so regardless how you feel about the stock (even though price target analysts are WAY higher) this is due for a rip. Not to mention this is a perfect situation for institutions to enter into ABCL at a pretty big discount from fair value etc.
I am temporarily waiting next few days watch it extremely closely then entering unless it breaks through the bottom.
Feel free to do your DD on ABCL they actually have really good positive pipelines just being held down.
CEMI - **ON HIGH ALERT** - OTM OPTIONS $5 CALLS - WEEKLY / DAILYAll,
I think CEMI is due for a huge run here oversold massively on almost all timeframes like daily/weekly. This has been building up and end of pattern now. I'd either scale in or get OTM options but further out.
ABCL - WW - SMALL OTM OPTIONSAll, ABCL in a pretty solid spot here imo. Definitely need conformation of bottom here, candle looks to be a reversal possibly. I would look at 17-20$ calls OTM longer term or leveraged stock position hold long with a very tight stop loss. Could drop one more level. Just watch, slap some alerts on it but ABCL definitely imo worth 20-22.
